DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06069622

Recruiting

Role of Caveolin 1 (CAV-1) Deficiency in Response to Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Treatment

The Role of Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Treatment of Overweight/Obese Individuals for Improving Adverse Cardiometabolic Phenotype Associated With CAV-1 Deficiency

Assets

GLP-1 / incretin class catch-all / Semaglutide

Listed sites

1

Recruiting sites

1

Enrollment

30

estimated

Study population

Obesity / overweight

Key I/E criterion

•BMI ≥30

Primary endpoints

•Systolic BP, change•Body weight, % change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06069622
Org study ID2023P002452

Timeline

Milestones

Study first posted2023-10-06actual
Study start2023-11-01actual
Last update posted2025-12-10actual
Primary completion2026-10-01estimated
Study completion2026-11-30estimated

Assets

Investigational agents

GLP-1 / incretin class catch-allSemaglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

Age ≥18 years, men and women who have body mass index (BMI) ≥30.0 kg/m2 or ≥27.0 kg/m2 with the presence of at least one of the weight-related comorbidities

Inclusion criteria

•Age ≥18 years, body mass index (BMI) ≥30.0 kg/m2 or ≥27.0 kg/m2 with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension, prediabetes, dyslipidemia, obstructive sleep apnea,
•Normal screening laboratory values,
•Systolic BP < 160 mmHg and diastolic BP < 95 mmHg as determined from measurement during screening, using a random-zero device in the clinic and normal electrocardiogram, use of anti-hypertensive medications will be allowed except for mineralocorticoid receptor antagonists.

Exclusion criteria

•Diabetes mellitus,
•Treatment with a glucose-lowering agent(s) or anti-obesity medication within 90 days of screening,
•Treatment with a GLP-1 receptor agonist within 180 days,
•Current treatment with beta-blocker, or steroids,
•Pregnancy,
•Personal history of pancreatitis,
•Personal history of cholelithiasis,
•Previous surgical obesity treatment,
•Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma,
•Medical illness other than hypertension, prediabetes, obstructive sleep apnea, or dyslipidemia,
•Alcohol intake >12 oz. per week,
•Tobacco, or recreational drug use

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
1
Cardiometabolic biomarkers
1
Other (unclassified)
1

Weight & body composition

1 endpoint
Primary/protocol endpoint

Weight loss response to GLP-1 RA treatment

Time frame:20 weeks

Body weight, % change

percent change from baseline, improvement

Cardiometabolic biomarkers

1 endpoint
Primary/protocol endpoint

Blood pressure response to GLP-1 RA treatment

Time frame:20 weeks

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Aldosterone response to GLP-1 RA treatment

Time frame:20 weeks

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.